Fibronostics has acquired STONE Diagnostics for an undisclosed amount, integrating its comprehensive laboratory services. This strategic corporate acquisition marks an expansion for Fibronostics within the diagnostic testing industry.
STONE Diagnostics, founded by Christopher Ridgeway, is a full-service laboratory based in Northwest Florida and New Orleans. The company focuses on empowering physicians and enlightening patients through its best-in-class technology, systems, and employees. STONE Diagnostics offers a broad range of services, including urine and oral fluid toxicology with extensive LC/MS/MS testing, customizable blood-based testing to determine root causes and assess baselines, and comprehensive pharmacogenetic (PgX) testing. It is a CAP-accredited leader in molecular diagnostics, known for its personalized service and in-network coverage for over 200 million lives.
This acquisition is strategic, allowing Fibronostics to integrate STONE Diagnostics' established regional presence, diverse testing portfolio, and robust client service. STONE Diagnostics' capabilities in urine and oral fluid toxicology, blood-based testing, and pharmacogenetics, alongside its CAP-accredited molecular diagnostics leadership and extensive in-network coverage, will significantly broaden Fibronostics' service offerings. Synergies are expected through expanded market reach and a more comprehensive diagnostic solution for physicians and patients.
The combined entity is poised to offer an even wider array of diagnostic services, aiming to enhance patient care and physician support across an expanded geographical footprint. The integration of STONE Diagnostics' advanced technology and patient-centric approach with Fibronostics' platform is expected to drive innovation and efficiency in the diagnostic laboratory sector.